Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. - Wikidata - awgldk - TriplyDB

Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.

Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.

http://www.wikidata.org/entity/Q43261590

about

Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma Tumor and stromal-based contributions to head and neck squamous cell carcinoma invasion Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Cost-Effectiveness Analysis of Elective Neck Dissection in Patients With Clinically Node-Negative Oral Cavity Cancer Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study.Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.Health-related quality of life and cancer clinical trials.Targeted therapy: a new approach for the treatment of locally advanced oropharyngeal cancer.Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal.Prognostic Impact of Epidermal Growth Factor Receptor Overexpression in Patients with Cervical Cancer: A Meta-Analysis.Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma EGFR status in oral squamous cell carcinoma: comparing immunohistochemistry, FISH and CISH detection in a case series study Targeting proliferation and survival pathways in head and neck cancer for therapeutic benefit Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.Quality-of-life considerations in treatment of unresectable, recurrent head and neck cancer.Molecular targeted therapies in head and neck cancer--an update of recent developments-A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers.Epidermal growth factor receptor as a biomarker for cervical cancer.Application of microfluidic systems in management of head and neck squamous cell carcinoma.Improving end-of-life care for head and neck cancer patients.Targeted therapy in head and neck cancer.Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance Pharmacotherapy of Anal Cancer.Reduced proliferation and colony formation of head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and hedgehog pathways.Mutation analysis of EGFR and its correlation with the HPV in Indian cervical cancer patients.Erlotinib and gefitinib responsiveness in head and neck cancer cell lines--a comparing analysis with cetuximab.3q26-29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes.EGFR copy number alterations in primary tumors, metastatic lymph nodes, and recurrent and multiple primary tumors in oral cavity squamous cell carcinoma.Combined chemotherapy and intensity-modulated radiotherapy for the treatment of head and neck cancers.Oncology Gold Standard® practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck.Zinc oxide nanoparticles antagonize the effect of Cetuximab on head and neck squamous cell carcinoma in vitro.Targeting HIF1α peri-operatively increased post-surgery survival in a tongue cancer animal model.Noncharged and Charged Monodendronised Perylene Bisimides as Highly Fluorescent Labels and their Bioconjugates.

P2860

Q26767182-87C67663-9C80-47FC-B70C-E93064E3F2CA Q26825164-DA53C146-B6DF-4278-900F-3682E97DB992 Q33650470-9CAAECE2-838B-4A48-88C3-3097B8800C1B Q33758611-6C21B6B9-3DA6-439A-854D-AB6D96909CD7 Q34497010-7FB0FC1D-5C1D-4ED2-B7D8-4707DA233EC0 Q34781075-60B9C476-AA88-4291-B2DD-5CDE5310CB6C Q35076356-44DCFC46-B532-4997-9458-4435266EFA2D Q36026004-947F66FB-9741-4D63-92C5-53219B88B3E3 Q36062576-B63E15EE-4AC3-447D-99BB-241992267123 Q36082772-95354D53-D902-4058-8E5E-EAAABD4E85F6 Q36214744-C65677BF-729A-4228-9FB0-9BCA9FB13108 Q36584164-E87E796D-C558-40E9-92BD-765DB5871DD6 Q36713669-275B9A9D-8137-469C-9319-FAFDB1A41EF3 Q36804537-04108A6F-298C-447C-AB9F-C3F60829C30A Q37705409-17CFDE53-5333-45D9-8812-0F4553977B74 Q37732457-91B3CAF3-FD57-4F7F-9F46-9ADDA4957FD0 Q37737013-0E8F259A-1513-498B-8C01-AA83D2C96C47 Q37843137-9D37FBB9-3E3F-4C2E-BEE4-4700CEFED890 Q37981633-541761AB-A0E6-4CED-824D-DD8A1A615780 Q37988564-0D6FE8B1-5DFE-484D-8A52-5842E0D616D8 Q37988981-44374936-3B24-4CA5-8FFE-F289004297C4 Q38118934-2CBDA8A2-912F-42A5-9F9E-AA79DBCAA4EE Q38647761-0617E7AF-06A4-4324-9E50-5DD54151D825 Q38720111-3354B4E3-8A42-4CA4-85B8-A2318D420C37 Q38804094-249F3708-3DE5-4053-92CA-B45007CE738F Q38841850-97E7D87D-04C1-4B82-B0BE-CF35DF519D82 Q39186868-D476E6E0-37E9-423E-86E6-6FDE822300CA Q41556469-EBA08E74-0EE0-4458-8CD2-9F725BCCF8D2 Q48867952-C0D7F679-4449-4624-B726-B542511FB1FD Q49777008-1687C81B-F263-442A-89EC-D3D33DF92154 Q50655554-A4DCE4EB-3C86-4B4F-BA87-74CE7154FD3A Q51019842-B8D1FA5B-0D78-4E11-B99D-871C280C2F29 Q52842193-15F1B6B5-F579-474C-8554-D9591BDEEE88

P2860

Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.

http://www.wikidata.org/entity/Q43261590

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.

@en

Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.

@nl

type

label

Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.

@en

Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.

@nl

prefLabel

Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.

@en

Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.

@nl

P1433

Q43261590-6D6BD4DA-4A56-4ABC-B556-3AE285029147

P1476

Q43261590-E5533632-789B-461B-ABB3-B104BFBF454A

P2093

Q43261590-60B94287-0667-4C05-A761-57B31D08BC5F

Q43261590-7BE6BA47-1141-4D05-AF6B-3BB05C7A5BF0

Q43261590-80561535-31C2-4087-B86A-0175297EDCD5

Q43261590-BB58CA16-6C4D-4EF7-8998-4A7E51479DB6

Q43261590-DA7DE644-7211-43EC-9753-D292A8ADAA83

P2860

Q43261590-0A51A505-1185-4498-8FD7-7CD7E9FCEC12

Q43261590-1B8AD9C4-60D8-4DEA-AC00-2E56478BAE12

Q43261590-2A8C162A-7D17-40DA-8709-A59C5C3633C0

Q43261590-2CEB6882-2E94-46F8-A928-473406F80967

Q43261590-39908920-DAE4-41FA-B09E-3AC564A3EF62

Q43261590-402A56D8-28E1-4D2D-BF36-E8B59477F611

Q43261590-40ABA73A-E338-411B-8C0F-BBBF83F843DE

Q43261590-53CAA6D7-DC47-416B-92A6-E29B1972C9BF

Q43261590-5D020F28-F66D-40B5-ADF3-DDDCD5A3D1C6

Q43261590-5D4F2D4A-562E-4CBF-9CD9-A3896802919B

P304

Q43261590-0E3BF1D6-979A-4E3B-8F5E-930E30A324CA

P31

Q43261590-1AB18089-EC84-44A9-BE10-226D0222B077

P356

Q43261590-BEAF1BE8-035C-4C2A-9788-3A6BEA08E61F

P433

Q43261590-F8AE16F3-8CDF-4E10-8B9F-AA1570D822D6

P478

Q43261590-0CCBDD7D-645E-4898-AEE6-D7A21606A0CA

P577

Q43261590-06CE8D09-203F-4267-94A0-D67B45BC5095

P698

Q43261590-B407D1A3-28B7-4CA3-A8C3-68615C263F01

P921

Q43261590-C25DA6AE-B5D4-4F2E-A213-15058ACD90F1

P356

P1433

Expert Review of Anticancer Therapy

P1476

Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.

@en

P2093

Almudena García-Castaño

http://www.w3.org/2001/XMLSchema#string

Fernando Rivera

http://www.w3.org/2001/XMLSchema#string

Lourdes Gutiérrez-Sanz

http://www.w3.org/2001/XMLSchema#string

Maria Eugenia Vega-Villegas

http://www.w3.org/2001/XMLSchema#string

Noelia Vega

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

The protein tyrosine kinase family of the human genome

Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

P304

1421-1428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.09.113

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19828002

http://www.w3.org/2001/XMLSchema#string

P921